603229 奥翔药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)8.9649.37114.09517.33312.254
总资产报酬率 ROA (%)6.8526.9709.64111.3309.061
投入资产回报率 ROIC (%)7.4757.87411.43313.57310.326

边际利润分析
销售毛利率 (%)56.92654.23355.04851.50154.787
营业利润率 (%)36.26130.32235.60733.70828.112
息税前利润/营业总收入 (%)35.45927.23831.47927.93928.989
净利润/营业总收入 (%)32.05026.00231.08630.78625.615

收益指标分析
经营活动净收益/利润总额(%)89.60091.51096.38298.04995.144
价值变动净收益/利润总额(%)8.26811.8090.2412.4737.317
营业外收支净额/利润总额(%)-0.380-0.393-0.021-0.725-0.477

偿债能力分析
流动比率 (X)2.8402.5342.1721.5251.924
速动比率 (X)2.1681.9391.6991.0951.465
资产负债率 (%)23.30023.82327.44336.89331.783
带息债务/全部投入资本 (%)16.34214.16714.95120.26320.519
股东权益/带息债务 (%)503.945596.424558.661384.038384.451
股东权益/负债合计 (%)329.190319.760264.394171.056214.630
利息保障倍数 (X)-53.372-9.187-7.639-5.05628.669

营运能力分析
应收账款周转天数 (天)83.28973.55158.96647.33435.325
存货周转天数 (天)400.430378.875336.194273.793303.018